Evidence map›Paper›PMID 41756920›Full record

ArticlebioRxiv : the preprint server for biology2026

Targeted shedding of extracellular membrane proteins by induced protease recruitment.

Zi Yao, Fangzhu Zhao, Kun Miao, Trenton M Peters-Clarke, Yun Zhang, Snehal D Ganjave, Angel L Vázquez-Maldonado, Yan Wu, Kaan Kumru, Hammam Jumaa and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zi YaoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Fangzhu ZhaoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3172-1340
Kun MiaoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Trenton M Peters-ClarkeDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9153-2525
Yun ZhangDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Snehal D GanjaveDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Angel L Vázquez-MaldonadoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Yan WuDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Kaan KumruDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Hammam JumaaDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Kevin K LeungDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2087-4974
James A WellsDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.

Funding

Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolutionR35GM122451 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2017 to 2026
$5.3M
Research Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1M
New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targetsR01CA248323 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2020 to 2026
$2.6M
Toward Understanding the Functional Landscape of Proteolysis at the Cell SurfaceF32CA298768 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trenton Peters-Clarke · 2025 to 2026
$155k
NCI NIH HHS F32 CA298768NCI NIH HHS R01 CA248323NIGMS NIH HHS R35 GM122451NIGMS NIH HHS T32 GM145460
6 · The paper itself

Abstract

Extracellular targeted protein degradation has emerged as a promising therapeutic modality to eliminate proteins of interest (POIs) at the cell surface, by using bifunctional molecules to recruit natural recycling receptors or membrane-bound E3 ligases that redirect POIs to the lysosome. Another natural mechanism involves extracellular proteases that cleave and shed extracellular domains. Here, we exploit this endogenous mechanism by engineering bispecific antibody

Identifiers

PMID41756920
PMCPMC12934945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.